Everist Genomics Awarded Admission to Johnson & Johnson (JNJ)'s Life Science Innovation Center
7/11/2012 9:50:42 AM
More...
|
Everist Genomics Announces Publication of Validation Study Confirming OncoDefender-CRC Independently Predicts Recurrence Risk for Early Stage Colorectal Cancer Patients
6/5/2012 10:10:03 AM
More...
|
Everist Genomics Forms JV Targeting Indian Market
5/22/2012 11:05:58 AM
More...
|
Everist Genomics Develops World's First Comprehensive Companion Diagnostics and Prognostics Portfolio for Early Diagnosis and Improved Treatment of Colorectal Cancer
3/14/2012 10:31:26 AM
More...
|
Everist Genomics Celebrates Origins and Future of Personalized Medicine
2/13/2012 10:20:12 AM
More...
|
Smartphone Technology Meets Personalized Medicine in Everist Genomics' CardioDefender Diagnostic System
1/30/2012 9:38:06 AM
More...
|
Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal Cancer
12/7/2011 9:56:37 AM
More...
|
Everist Genomics Announces Acquisition of Angiologix, Inc.
10/31/2011 10:52:57 AM
More...
|
Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
6/3/2011 10:19:44 AM
More...
|
Everist Genomics Announces Worldwide Availability of OncoDefender(TM)-CRC
3/28/2011 6:44:03 AM
More...
|
|